

Stephen E M Langley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8035830/publications.pdf>

Version: 2024-02-01

23
papers

411
citations

933264

10
h-index

839398

18
g-index

23
all docs

23
docs citations

23
times ranked

572
citing authors

#	ARTICLE	IF	CITATIONS
1	Robot-assisted salvage seminal vesicle excision for isolated recurrence after low-dose-rate prostate brachytherapy. <i>BJU International</i> , 2022, 129, 731-736.	1.3	3
2	Long-term survival after low-dose-rate brachytherapy for prostate cancer: the Royal Surrey experience. <i>BJU International</i> , 2022, 129, 723-730.	1.3	2
3	Low-Dose-Rate Prostate Brachytherapy (LDR-PB) adopts postsurgical PSA value for definition of cure. <i>BJUI Compass</i> , 2021, 2, 9-10.	0.7	5
4	Low-dose-rate brachytherapy for prostate cancer stands the test of time – the Swiss experience. <i>BJU International</i> , 2020, 125, 750-751.	1.3	0
5	Investigating the associations of mucosal P2Y6 receptor expression and urinary ATP and ADP concentrations, with symptoms of overactive bladder. <i>Neurourology and Urodynamics</i> , 2020, 39, 926-934.	0.8	4
6	Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse. <i>BJU International</i> , 2018, 122, 610-617.	1.3	8
7	Long-term oncological outcomes and toxicity in 597 men aged >=60 years at time of low-dose-rate brachytherapy for localised prostate cancer. <i>BJU International</i> , 2018, 121, 38-45.	1.3	27
8	Brachytherapy for Prostate Cancer. , 2018, , 87-98.		0
9	Risk-assessed exercise and diet in prostate cancer survivors: Consequences of cancer treatment on cardiopulmonary fitness and cardiovascular risk.. <i>Journal of Clinical Oncology</i> , 2017, 35, 142-142.	0.8	0
10	Modified transurethral resection of the prostate (<sc>TURP</sc>) for men with moderate lower urinary tract symptoms (<sc>LUTS</sc>) before brachytherapy is safe and feasible. <i>BJU International</i> , 2015, 115, 580-586.	1.3	14
11	Brachytherapy for Prostate Cancer. , 2015, , 743-772.		0
12	Importance of <sc><i>HOX</i></sc> genes in normal prostate gland formation, prostate cancer development and its early detection. <i>BJU International</i> , 2014, 113, 535-540.	1.3	51
13	Does Prostate HistoScanning accurately identify prostate cancer, measure tumour volume and assess pathological stage prior to radical prostatectomy?. <i>Journal of Clinical Urology</i> , 2013, 6, 395-402.	0.1	8
14	4D Brachytherapy, a novel real-time prostate brachytherapy technique using stranded and loose seeds. <i>BJU International</i> , 2012, 109, 1-6.	1.3	18
15	Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. <i>BJU International</i> , 2012, 109, 7-16.	1.3	104
16	Long-term toxicity and quality of life up to 10 years after low-dose rate brachytherapy for prostate cancer. <i>BJU International</i> , 2012, 109, 994-1000.	1.3	26
17	The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance. <i>BJU International</i> , 2012, 109, 1170-1176.	1.3	67
18	Novel prostate brachytherapy technique: Improved dosimetric and clinical outcome. <i>Radiotherapy and Oncology</i> , 2008, 88, 121-126.	0.3	18

#	ARTICLE	IF	CITATIONS
19	Are prostatic biopsies necessary in men aged $\geq 80\frac{1}{2}$ years?. BJU International, 2007, 99, 335-338.	1.3	11
20	Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database. BJU International, 2007, 99, 1398-1403.	1.3	19
21	Biochemical (prostate-specific antigen) relapse-free survival and toxicity after ^{125}I low-dose-rate prostate brachytherapy. BJU International, 2006, 98, 1210-1215.	1.3	16
22	Prostate cancer treatment. Permanent low-dose rate prostate brachytherapy. Annals of the Royal College of Surgeons of England, 2006, 88, 442-4.	0.3	0
23	Fertility after prostate brachytherapy. BJU International, 2005, 96, 915-915.	1.3	10